{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:32Z","timestamp":1707524372940},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,13]]},"DOI":"10.7759\/cureus.18740","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T12:45:21Z","timestamp":1634129121000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Sacubitril\/Valsartan in the Setting of Acute Heart Failure: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Moiud","family":"Mohyeldin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena B","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Boorenie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deya","family":"Abureesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saman","family":"Ejaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Durrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-9842(02)00017-x","article-title":"Acute heart failure: a novel approach to its pathogenesis and treatment","volume":"4","author":"Cotter G","year":"2002","unstructured":"Cotter G, Moshkovitz Y, Milovanov O, et al.. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002, 4:227-234. 10.1016\/s1388-9842(02)00017-x","journal-title":"Eur J Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy AP","year":"2014","unstructured":"Ambrosy AP, Fonarow GC, Butler J, et al.. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014, 63:1123-1133. 10.1016\/j.jacc.2013.11.053","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.03.051","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"46","author":"Abraham WT","year":"2005","unstructured":"Abraham WT, Adams KF, Fonarow GC, et al.. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005, 46:57-64. 10.1016\/j.jacc.2005.03.051","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.04.028","article-title":"Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"52","author":"Abraham WT","year":"2008","unstructured":"Abraham WT, Fonarow GC, Albert NM, et al.. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008, 52:347-356. 10.1016\/j.jacc.2008.04.028","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl193","article-title":"EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population","volume":"27","author":"Nieminen MS","year":"2006","unstructured":"Nieminen MS, Brutsaert D, Dickstein K, et al.. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006, 27:2725-2736. 10.1093\/eurheartj\/ehl193","journal-title":"Eur Heart J"},{"key":"ref6","unstructured":"entresto.pdf . (2015). Accessed. July 15, 2021: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/entresto.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-548. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1159","article-title":"The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions","volume":"20","author":"Ambrosy AP","year":"2018","unstructured":"Ambrosy AP, Mentz RJ, Fiuzat M, et al.. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail. 2018, 20:963-972. 10.1002\/ejhf.1159","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.09.005","article-title":"A standardized and comprehensive approach to the management of cardiogenic shock","volume":"8","author":"Tehrani BN","year":"2020","unstructured":"Tehrani BN, Truesdell AG, Psotka MA, et al.. A standardized and comprehensive approach to the management of cardiogenic shock. JACC Heart Fail. 2020, 8:879-891. 10.1016\/j.jchf.2020.09.005","journal-title":"JACC Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.4665","article-title":"Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: secondary analysis of the open-label extension of the PIONEER-HF trial","volume":"5","author":"DeVore AD","year":"2020","unstructured":"DeVore AD, Braunwald E, Morrow DA, et al.. Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: secondary analysis of the open-label extension of the PIONEER-HF trial. JAMA Cardiol. 2020, 5:202-207. 10.1001\/jamacardio.2019.4665","journal-title":"JAMA Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.07.227","article-title":"Sacubitril\/valsartan initiated in black patients admitted for acute decompensated heart failure reduced nt-probnp, was safe and led to improved clinical outcomes- a secondary analysis of the PIONEER-HF trial","volume":"25","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Ambrosy A, Morrow DA, et al.. Sacubitril\/valsartan initiated in black patients admitted for acute decompensated heart failure reduced nt-probnp, was safe and led to improved clinical outcomes- a secondary analysis of the PIONEER-HF trial. J Card Fail. 2019, 25:S80. 10.1016\/j.cardfail.2019.07.227","journal-title":"J Card Fail"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter R","year":"2019","unstructured":"Wachter R, Senni M, Belohlavek J, et al.. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019, 21:998-1007. 10.1002\/ejhf.1498","journal-title":"Eur J Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1670","article-title":"Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study","volume":"22","author":"Senni M","year":"2020","unstructured":"Senni M, Wachter R, Witte KK, et al.. Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur J Heart Fail. 2020, 22:303-312. 10.1002\/ejhf.1670","journal-title":"Eur J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025621","article-title":"A study of the sequential treatment of acute heart failure with sacubitril\/valsartan by recombinant human brain natriuretic peptide: a randomized controlled trial","volume":"100","author":"Pang Z","year":"2021","unstructured":"Pang Z, Pan C, Yao Z, et al.. A study of the sequential treatment of acute heart failure with sacubitril\/valsartan by recombinant human brain natriuretic peptide: a randomized controlled trial. Medicine (Baltimore). 2021, 100:e25621. 10.1097\/MD.0000000000025621","journal-title":"Medicine (Baltimore)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006645","article-title":"Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction","volume":"13","author":"Fudim M","year":"2020","unstructured":"Fudim M, Sayeed S, Xu H, et al.. Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction. Circ Heart Fail. 2020, 13:e006645. 10.1161\/CIRCHEARTFAILURE.119.006645","journal-title":"Circ Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12676","article-title":"Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure","volume":"7","author":"Carballo D","year":"2020","unstructured":"Carballo D, Stirnemann J, Garin N, Marti C, Serratrice J, Carballo S. Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure. ESC Heart Fail. 2020, 7:1282-1290. 10.1002\/ehf2.12676","journal-title":"ESC Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000546","article-title":"The evolution of guideline-directed medical therapy among decompensated HFrEF patients in sacubitril\/valsartan era: medical expenses and clinical effectiveness","volume":"84","author":"Liang HW","year":"2021","unstructured":"Liang HW, Liao CT, Lin WY, et al.. The evolution of guideline-directed medical therapy among decompensated HFrEF patients in sacubitril\/valsartan era: medical expenses and clinical effectiveness. J Chin Med Assoc. 2021, 84:588-595. 10.1097\/JCMA.0000000000000546","journal-title":"J Chin Med Assoc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.01.1239","article-title":"Beneficial acute hemodynamic effects of sacubitril-valsartan in patients with low-cardiac output including significant improvement in PAPi","volume":"39","author":"Martyn T","year":"2020","unstructured":"Martyn T, Faulkenberg KD, Albert CL, et al.. Beneficial acute hemodynamic effects of sacubitril-valsartan in patients with low-cardiac output including significant improvement in PAPi. J Heart LungTransplant. 2020, 39:S54. 10.1016\/j.healun.2020.01.1239","journal-title":"J Heart LungTransplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.12.013","article-title":"Acute hemodynamic effects of sacubitril-valsartan in heart failure patients receiving intravenous vasodilator and inotropic therapy","volume":"27","author":"Martyn T","year":"2021","unstructured":"Martyn T, Faulkenberg KD, Albert CL, et al.. Acute hemodynamic effects of sacubitril-valsartan in heart failure patients receiving intravenous vasodilator and inotropic therapy. J Card Fail. 2021, 27:368-372. 10.1016\/j.cardfail.2020.12.013","journal-title":"J Card Fail"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.07.206","article-title":"Safety of initiation of sacubitril\/valsartan in ICU patients with advanced decompensated heart failure","volume":"25","author":"Yaranov DM","year":"2019","unstructured":"Yaranov DM, Albert CL, Gonzalez MH, Martyn T, Faulkenberg K, Tang WH, Starling R. Safety of initiation of sacubitril\/valsartan in ICU patients with advanced decompensated heart failure. J CardFail. 2019, 25:S72. 10.1016\/j.cardfail.2019.07.206","journal-title":"J CardFail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2020.08.014","article-title":"Safety and tolerability of sacubitril\/valsartan initiation in inpatient versus outpatient setting: a retrospective real world study","volume":"30","author":"Chng BL","year":"2021","unstructured":"Chng BL, Hon JS, Chan H, Zheng Y, Gao F, Teo LY, Sim KL. Safety and tolerability of sacubitril\/valsartan initiation in inpatient versus outpatient setting: a retrospective real world study. Heart Lung Circ. 2021, 30:674-682. 10.1016\/j.hlc.2020.08.014","journal-title":"Heart Lung Circ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019878948","article-title":"Risk factors for intolerance of inpatient sacubitril\/valsartan initiation","volume":"34","author":"Akerman CC","year":"2021","unstructured":"Akerman CC, Beavers JC. Risk factors for intolerance of inpatient sacubitril\/valsartan initiation. J Pharm Pract. 2021, 34:454-458. 10.1177\/0897190019878948","journal-title":"J Pharm Pract"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2019.1708638","article-title":"Evaluating the safety and tolerability of inpatient sacubitril\/valsartan initiation in a community hospital","volume":"10","author":"Peppin KL","year":"2020","unstructured":"Peppin KL, Tellor KB, Armbruster AL, Schwarze MW. Evaluating the safety and tolerability of inpatient sacubitril\/valsartan initiation in a community hospital. J Community Hosp Intern Med Perspect. 2020, 10:38-44. 10.1080\/20009666.2019.1708638","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00908-4","article-title":"Early initiation of sacubitril\/valsartan in patients with chronic heart failure after acute decompensation: a case series analysis","volume":"40","author":"Acanfora D","year":"2020","unstructured":"Acanfora D, Scicchitano P, Acanfora C, et al.. Early initiation of sacubitril\/valsartan in patients with chronic heart failure after acute decompensation: a case series analysis. Clin Drug Investig. 2020, 40:493-501. 10.1007\/s40261-020-00908-4","journal-title":"Clin Drug Investig"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.34172\/jcvtr.2020.53","article-title":"Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: a case series","volume":"12","author":"Taghavi S","year":"2020","unstructured":"Taghavi S, Chenaghlou M, Mirtajaddini M, Amin A, Naderi N. Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: a case series. J Cardiovasc Thorac Res. 2020, 12:334-336. 10.34172\/jcvtr.2020.53","journal-title":"J Cardiovasc Thorac Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytaa530","article-title":"The power of optimal medical therapy using angiotensin receptor-neprilysin inhibitor in acute decompensated heart failure, sparing a critical patient open-heart surgery with a device therapy: a case report","volume":"5","author":"Gerges F","year":"2021","unstructured":"Gerges F, Komaranchath A, Al Bakshy F, Almaghraby A. The power of optimal medical therapy using angiotensin receptor-neprilysin inhibitor in acute decompensated heart failure, sparing a critical patient open-heart surgery with a device therapy: a case report. Eur Heart J Case Rep. 2021, 5:ytaa530. 10.1093\/ehjcr\/ytaa530","journal-title":"Eur Heart J Case Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.639551","article-title":"Case report: low dose of valsartan\/sacubitril leads to successful reversal of acute heart failure in chemotherapy-induced cardiomyopathy","volume":"9","author":"Lo SH","year":"2021","unstructured":"Lo SH, Liu YC, Dai ZK, Chen IC, Wu YH, Hsu JH. Case report: low dose of valsartan\/sacubitril leads to successful reversal of acute heart failure in chemotherapy-induced cardiomyopathy. Front Pediatr. 2021, 9:639551. 10.3389\/fped.2021.639551","journal-title":"Front Pediatr"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12219","article-title":"Use of sacubitril\/valsartan in acute decompensated heart failure: a case report","volume":"5","author":"Bell TD","year":"2018","unstructured":"Bell TD, Mazer AJ, Miller PE, Strich JR, Sachdev V, Wright ME, Solomon MA. Use of sacubitril\/valsartan in acute decompensated heart failure: a case report. ESC Heart Fail. 2018, 5:184-188. 10.1002\/ehf2.12219","journal-title":"ESC Heart Fail"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8231576","article-title":"Sacubitril\/valsartanstive heart failure: cardiogenic shock","volume":"2018","author":"Rawal HA","year":"2018","unstructured":"Rawal HA, Kocheril AG. Sacubitril\/valsartanstive heart failure: cardiogenic shock. Case Rep Cardiol. 2018, 2018:8231576. 10.1155\/2018\/8231576","journal-title":"Case Rep Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytaa233","article-title":"Crossing the chasm: caution for use of angiotensin receptor-neprilysin inhibition in patients with cardiogenic shock - a case report","volume":"4","author":"Almazroa L","year":"2020","unstructured":"Almazroa L, Mihajlovic V, Lawler PR, Luk A. Crossing the chasm: caution for use of angiotensin receptor-neprilysin inhibition in patients with cardiogenic shock - a case report. Eur Heart J Case Rep. 2020, 4:1-4. 10.1093\/ehjcr\/ytaa233","journal-title":"Eur Heart J Case Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10115-8","article-title":"Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper","author":"Ntalianis A","year":"2021","unstructured":"Ntalianis A, Chrysohoou C, Giannakoulas G, et al.. Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. Heart Fail Rev. 2021, 1-13. 10.1007\/s10741-021-10115-8","journal-title":"Heart Fail Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/73131-efficacy-of-sacubitrilvalsartan-in-the-setting-of-acute-heart-failure-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:46Z","timestamp":1707507286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/73131-efficacy-of-sacubitrilvalsartan-in-the-setting-of-acute-heart-failure-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.18740","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,13]]}}}